Back to Search Start Over

Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation

Authors :
Adrie van Bokhoven
Howard Li
Erin L. Schenk
Amber M. Johnson
Andrea Abeyta Osypuk
Terry L. Ng
Elena W Y Hsieh
Raphael A. Nemenoff
D. Ross Camidge
Source :
Journal of Thoracic Oncology. 16:486-491
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Introduction Symptomatic early onset pulmonary events (EOPEs) were observed in 3% to 6% of patients within 1 week of starting brigatinib at 90 mg daily for 7 days followed by 180 mg daily. We conducted a prospective observational cohort study to measure pulmonary function changes on initiating brigatinib. Methods Patients initiating brigatinib were eligible. Pulmonary function test (PFT) with diffusing capacity for carbon monoxide (DLCO), Borg dyspnea scale, six-minute walk test, and blood draw for cytometry by time-of-flight were performed at baseline, day 2, and day 8 plus or minus day 15 of brigatinib. The primary end point was the incidence of PFT-defined EOPEs, prespecified as greater than or equal to 20% DLCO reduction from baseline. An interim analysis was performed owing to a higher than expected incidence of DLCO reduction. Results A total of 90% (nine of 10) experienced DLCO reduction with the nadir occurring on day 2 or day 8. Median DLCO nadir was −13.33% from baseline (range: −34.44 to −5.00). Three participants met the PFT-defined EOPE criteria. All patients, including these three, were asymptomatic, none required brigatinib interruption or dose reduction, and all patients escalated to 180 mg without further issues. Despite continued dosing, by day 15, all assessed patients experienced DLCO recovery. Dyspnea and six-minute walk test results did not correlate with DLCO changes. Patients with a PFT-defined EOPE had significantly higher levels of activated neutrophils at baseline and day 8. Conclusions DLCO reduction occurred in 90% during the first 8 days of brigatinib dosing without any related symptoms. DLCO improved in all six patients assessed at day 15 despite continued dosing and dose escalation. Pretreatment levels of neutrophil activation should be explored as a biomarker for developing EOPEs.

Details

ISSN :
15560864
Volume :
16
Database :
OpenAIRE
Journal :
Journal of Thoracic Oncology
Accession number :
edsair.doi...........539bb90f20c928e6b0f130c0eb9d235a